37 Results for "

DLL3

" in MedChemExpress (MCE) Product Catalog:
Products (37)

37 Results for "DLL3" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-P99575
CAS No.: 2307488-83-9
Synonyms: AMG-757

Target:  

Notch

Research Areas:  

Inflammation/Immunology Cancer

Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
1
1 Cited Publications
Cat. No.: HY-P99043
CAS No.: 1613313-01-1
Synonyms: SC-0001

Target:  

Notch

Research Areas:  

Cancer

Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC) .
Cat. No.: HY-W1126504
CAS No.: 3066864-32-9
Synonyms: MC339
Target:  

Notch

Research Areas:  

Cancer

ETN029 (MC339) is a selective DLL3 ligand. ETN029 labeled with 225Ac has dose-dependent cytotoxicity in SCLC, NEPC and metastatic melanoma cells and increases the phosphorylation of H2AX expression. ETN029 labeled with 177Lu shows rapid uptake persistent tumor retention and favorable tumor-to-kidney ratio. ETN029 can be used for cancers like SCLC and NEPC imaging and research .
Cat. No.: HY-P990932
CAS No.: 2851943-09-2
Synonyms: BI 764532; OBT 620

Target:  

CD3

Research Areas:  

Cancer

Obrixtamig (BI 764532; OBT 620) is an CD3E/DLL3-targeting L-κ-G1-h-CH2-CH3_L-λ-G1-h-CH2-CH3 type human antibody. Obrixtamig is a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager. Obrixtamig can be used for research of DLL3-positive small cell lung cancer .
Cat. No.: HY-164729
FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The Kd value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .
Cat. No.: HY-P991731
Synonyms: ZG006

Target:  

CD3 Notch

Research Areas:  

Neurological Disease Cancer

Alveltamig (ZG006) is a trispecific T cell engager targeting Delta-like ligand 3 (DLL3)/CD3, mediating T cell-specific killing of DLL3-expressing tumor cells. Alveltamig can be used for the researches of small cell lung cancer and neuroendocrine carcinoma .
Cat. No.: HY-132257
CAS No.: 1613313-09-9
Synonyms: SC-002
Research Areas:  

Cancer

Rovalpituzumab tesirine (SC-002) is an antibody-drug conjugate (ADC) with anticancer effects. Rovalpituzumab tesirine contains a DLL3-targeting antibody Rovalpituzumab (HY-P99043) tethered to a cytotoxic agent pyrrolobenzodiazepine by means of a protease-cleavable linker. Rovalpituzumab tesirine can be used for the stduy of small cell lung cancer (SCLC) .
Cat. No.: HY-P990104

Target:  

Notch

Research Areas:  

Inflammation/Immunology Cancer

Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) is the anti-DLL3 arm of the bispecific T-cell engager (BiTE) antibody-Tarlatamab (AMG-757) (HY-P99575). Tarlatamab targets both DLL3 and CD3.
Cat. No.: HY-159072
CAS No.: 2575682-08-3
Purity:  96.22%
Research Areas:  

Cancer

Mal-Val-Ala-PAB-N(SO2Me)-Exatecan (Compound LE14) is a conjugate of an ADC toxin Exatecan (HY-13631) and a linker Mal-Val-Ala-PAB-N(SO2Me). Mal-Val-Ala-PAB-N(SO2Me)-Exatecan can be used for synthesis of ADC FZ-AD005. FZ-AD005 is a delta-like ligand 3 (DLL3, KD=58.3 pM) targeting ADC, that exhibits antitumor efficacy against SCLC cancer .
Cat. No.: HY-P990981
CAS No.: 2930861-48-4
Synonyms: ALPS-12; RG-6524; RO 7616789

Target:  

CD3

Research Areas:  

Inflammation/Immunology Cancer

Clesitamig (ALPS-12) is a trispecific T cell engager with two CD3/CD137 dual-specific Fabs and one DLL3 Fab. Clesitamig engages CD3 and CD137 on T cells to activate and co-stimulate T cells, promoting their proliferation, survival, and antitumor activity. Clesitamig binds to DLL3 on tumor cells for tumor-specific recognition. Clesitamig can be used for the research of small cell lung cancer (SCLC) .
Cat. No.: HY-P990920
CAS No.: 2851862-91-2
Synonyms: MK-6070; HPN328

Target:  

CD3

Research Areas:  

Cancer

HY-P990920 is an CD3E/ALB/DLL3-targeting (scFv-heavy-lamdba)-VH-VH' type chimeric humanized antibody .
Cat. No.: HY-P990896

Target:  

ADC Antibodies

Research Areas:  

Cancer

FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729) .
Cat. No.: HY-P990401

Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology

The Anti-DLL3 Antibody is a humanized antibody expressed in CHO, targeting DLL3. The predicted molecular weight (MW) of the Anti-DLL3 Antibody is 146.36 kDa. The isotype control for the Anti-DLL3 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Cat. No.: HY-RS03809
Research Areas:  

Others

DLL3 Human Pre-designed siRNA Set A contains three designed siRNAs for DLL3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-RS16720
Research Areas:  

Others

Dll3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dll3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-RS23156
Research Areas:  

Others

Dll3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Dll3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-P991016
CAS No.: 2928515-21-1
Synonyms: PT-217

Target:  

CD47

Research Areas:  

Inflammation/Immunology

Peluntamig (PT-217) is a bispecific antibody targeting DLL3 and CD47. The antibody arms of Peluntamig specifically bind to DLL3 on small cell lung cancer tumor cells while blocking the CD47-SIRPa interaction, thereby effectively stimulating macrophage phagocytosis and inducing NK cell-mediated cytotoxicity. Peluntamig exhibits significant anti-tumor activity against small cell lung cancer and also has favorable safety profiles. Peluntamig can be used in a variety of tumor-related studies including those on small cell lung cancer and L1210 leukemia .
Cat. No.: HY-P991173

Target:  

Notch

Research Areas:  

Cancer

AMG-119 is a humanized IgG1 monoclonal antibody that targets delta-like ligand 3 (DLL3). AMG-119 can be used for the study of relapsed/refractory (R/R) small cell lung cancer (SCLC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Cat. No.: HY-P992148
CAS No.: 3058592-86-9
Synonyms: ZL-1310 Antibody

Target:  

Notch

Research Areas:  

Cancer

Zocilurtatug is a human monoclonal antibody against DLL3. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Cat. No.: HY-P77641
Purity:  ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: Delta3; DLL3; Pudgy; SCDO1; SCDO1delta3
Species:  
Source: